Watson Pharmaceuticals Invests in $15M New Jersey Expansion
05/27/2010
"Over the past year, we have outgrown our current administrative headquarters site, as our U.S. and global business has rapidly grown," said Paul Biscaro, Watson president and CEO. "This new facility will ensure that we have a single location for the leadership and shared services functions that are driving our global growth."
New Jersey's Business Employment Incentive Program (BEIP) has extended Watson a grant of approximately $7.3 million over the next 10 years from the state's Economic Development Authority. It has also been approved for a $290,000 Business Retention and Relocation Assistance Grant (BRRAG) to retain 200 jobs in New Jersey.
Watson was the country's third largest producer of generic drugs in 2009 based on prescriptions dispensed. It specializes in drugs for urology and women's health.
Project Announcements
Spartan Composites Plans Saltillo, Mississippi, Manufacturing Operations
02/14/2026
Hydrite Purchases Plans Laurens, South Carolina, Operations
02/13/2026
Blue Pony Energy Plans Lovington, New Mexico, Synthetic Fuel Operations
02/13/2026
James Composites Plans Marshall County. Kentucky, Manufacturing Operations
02/13/2026
Joby Aviation Plans Vandalia, Ohio, Operations
02/09/2026
Siemens Energy Plans Fort Payne, Alabama, Manufacturing Operations
02/09/2026
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Data Centers in 2025: When Power Became the Gatekeeper
Q4 2025
-
Speed Built In—The Real Differentiator for 2026 Site Selection Projects
Q1 2026
-
Preparing for the Next USMCA Shake-Up
Q4 2025
-
Tariff Shockwaves Hit the Industrial Sector
Q4 2025
-
The New Industrial Revolution in Biotech
Q4 2025
-
Strategic Industries at the Crossroads: Defense, Aerospace, and Maritime Enter 2026
Q1 2026